FDA Inspection
Edge Pharma, LLCEdge Pharma, LLC – FDA Inspection, Nov 30, 2021
Record Details
This FDA Inspection record concerns Edge Pharma, LLC, with an inspection on November 30, 2021, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Edge Pharma, LLC
- Inspection Date
- November 30, 2021
- Product Type
- Drugs
View Company Profile
ID · 81abe56f-7f3d-4386-a02b-60f140ce309b
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1157813
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
13- 21 CFR 211.68(b)Computer control of master formula records
- 21 CFR 211.42(c)(10)(vi)Equipment to control conditions
- 21 CFR 211.42(c)(10)(v)Cleaning System
- 21 CFR 211.42(a)Buildings of Suitable Size, Construction, Location
- 21 CFR 211.58Buildings not maintained in good state of repair
- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.68(a)Calibration/Inspection/Checking not done
- 21 CFR 211.167(a)Sterility/pyrogens - test methods written, followed
- Drug product label, outsourcer facility
- 21 CFR 211.192Investigations of discrepancies, failures
Showing 10 of 13 citations.
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Edge Pharma, LLC
3| Date | Classification | Office | Project area |
|---|---|---|---|
| March 8, 2018 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 20, 2017 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 20, 2014 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Edge Pharma, LLC
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.